Información del artículo
Numerosas evidencias han mostrado el papel deletéreo de angiotensina II en la lesión orgánica del paciente hipertenso. Así, el bloqueo del sistema renina-angiotensina se ha mostrado muy útil en la protección cardiovascular. Estudios en diabéticos con microalbuminuria (IRMA II) o nefropatía (RENAAL, IDNT) han demostrado la utilidad de los antagonistas de los receptores de la angiotensina II (ARA-II) en la protección cardiovascular del diabético. Tres grandes estudios han analizado la utilidad de ARA-II en la hipertensión: LIFE, SCOPE y VALUE. Hay que destacar que, hasta el momento, LIFE es el único estudio en que un fármaco antihipertensivo (ARA-II) se ha mostrado superior a otro (bloqueador beta) en términos de reducción de morbimortalidad, y los beneficios se han debido sobre todo a una significativa reducción del riesgo de ictus. El estudio SCOPE pudo también sugerir un cierto efecto protector de los ARA-II frente a eventos cerebrovasculares. Por último, VALUE ha destacado la relevancia de un adecuado y rápido control tensional en los hipertensos de alto riesgo pero, además, ha confirmado la utilidad de los ARA-II en aspectos que pueden ser muy importantes en la hipertensión, como la prevención de la diabetes. Con la información actualmente disponible, los ARA-II se muestran como fármacos antihipertensivos muy útiles, no sólo por su buena eficacia y excelente tolerabilidad, sino también por ofrecer efectos beneficiosos más allá de la propia reducción tensional.
Palabras clave:
Hipertensión arterial
Neuropatía
Diabetes
Hipertrofia ventricular izquierda
Antagonistas de los receptores de la angiotensina II
Numerous studies have shown the deleterious role of angiotensin II in organic lesions of hypertensive patients. Thus, the system renin-angiotensin blockade has been shown to be highly useful in cardiovascular protection. Studies in diabetics with microalbuminuria (IRMA II) or kidney disease (RENAAL, IDNT) have demonstrated the utility of angiotensin receptor blockers (ARB) in cardiovascular protection in diabetics. Three large studies have analyzed the utility of ARA II in hypertension: LIFE, SCOPE, and VALUE. Notably, to date, LIFE is the only study in which an antihypertensive drug (ARB) has been shown to be superior to another (beta-blocker) in reducing morbidity and mortality, benefits principally due to a significant reduction in the risk of stroke. The SCOPE study also suggested a certain protective effect of ARB against stroke. Lastly, VALUE has highlighted the importance of sufficient and rapid blood pressure control in hypertensive patients at high risk and has also confirmed the utility of ARB in factors that could be important in hypertension, such as diabetes prevention. Based on the currently available information, ARB have been shown to be highly useful antihypertensive drugs, not only because of their good efficacy and excellent tolerability, but also because they provide other beneficial effects in addition to blood pressure reduction.
Key words:
Hypertension
Nephropathy
Diabetes
Left ventricular hypertrophy
Angiotensin II receptor antagonists
El Texto completo está disponible en PDF
Bibliografía
[1.]
J.R. Benegas, F. Rodríguez-Artalejo, J.J. De la Cruz Troca, P. Guallar-Castillón, J. Del Rey Calero.
La presión arterial en España. Distribución, grado de conocimiento, control y beneficios de una reducción en los niveles medios de presión arterial.
Hipertensión, 32 (1999), pp. 908-1002
[2.]
J.R. González Juanatey, E. Alegría Ezquerra, J.V. Lozano Vidal, J.L. Llisterri Caro, J.M. García Acuña, I. González Maqueda.
Impacto de la hipertensión en las cardiopatías en España. Estudio CARDIOTENS 1999.
Rev Esp Cardiol, 54 (2001), pp. 139-149
[3.]
Ministerio de Sanidad y Consumo y Sociedad. Liga Española de Hipertensión arterial. Consenso para el control de la presión arterial en España. Madrid, 1996.
[4.]
Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure.
The sixth report of the Joint National Committee on detection, evaluation, and treatment of high blood pressure (JNC-VI).
Arch Intern Med, 157 (1997), pp. 2313-2446
[5.]
Guidelines Subcommittee.
1999 World Health Organization-International Society of Hypertension guidelines for the management of hypertension.
J Hypertens, 17 (1999), pp. 151-183
[6.]
V. Barrios, L.M. Ruilope.
Hypertension with left ventricular hypertrophy/ diastolic dysfunction.
Clinical cases in hypertension. Specific treatment strategies II, pp. 16-22
[7.]
L.H. Laragh, J.E. Sealy.
The renin-angiotensin-aldosterone system in hypertensive disorders: a key to two forms of arteriolar vasoconstriction and a possible clue to risk of vascular injury (heart attack and stroke) and prognosis.
Hypertension: pathophysiology, diagnosis and management, pp. 1329-1348
[8.]
C. Zitnay, H.M. Siragy.
Action of angiotensin receptor subtypes on the renal tubules and vasculature: implications for volume homeostasis and atherosclerosis.
Miner Electrolyte Metab, 24 (1998), pp. 362-370
[9.]
M.A. Bermam, M.F. Walh, J.R. Sowers.
Angiotensin II biochemistry and physiology. Update on angiotensin II receptor blockers.
Cardiovasc Rev, 15 (1997), pp. 75-100
[10.]
S. MacMahon, A. Rodgers.
The effects of blood pressure reduction in older patients: an overview of five randomised controlled trials in elderly hypertensive.
Clin Exp Hypertens, 15 (1993), pp. 967-978
[11.]
B. Neal, S. MacMahon, N. Chapman.
Blood pressure lowering treatment trialists collaboration. Effects of ACE inhibitors, calcium antagonists and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials.
Lancet, 356 (2000), pp. 1955-1964
[12.]
G. Maschio, D. Alberti, G. Janin, F. Locatelli, J.F. Mann, M. Motolese, et al.
The angiotensin-converting-enzyme inhibition in progressive renal insufficiency Study Group.
N Engl J Med, 334 (1996), pp. 939-945
[13.]
M.A. Pfeffer, E. Braunwald, L.A. Moyé, L. Basta, E.J. Brown, T.E. Cuddy, On behalf of the SAVE Investigators, et al.
The effect of captopril of morbidity and mortality in patients with left ventricular dysfunction following myocardial infarction. Results of the Survival and Ventricular Enlargement (SAVE) trial.
N Engl J Med, 327 (1992), pp. 669-677
[14.]
The Heart Outcomes Prevention Evaluation study investigators.
Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high risk patients.
N Engl J Med, 342 (2000), pp. 45-153
[15.]
The SOLVD Investigators.
Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fraction.
N Engl J Med, 327 (1992), pp. 685-691
[16.]
E.J. Lewis, L.G. Hunsicker, R.P. Bain, R.D. Rohde.
The effect of angiotensin- converting-enzyme inhibition on diabetic nephropathy: The Collaborative Study Group.
N Engl J Med, 329 (1993), pp. 1456-1462
[17.]
PROGRESS Collaborative Group.
Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack.
Lancet, 358 (2001), pp. 1033-1041
[18.]
L. Hansson, L.H. Lindholm, L. Niskanen, J. Lanke, T. Hedner, A. Niklason, et al.
Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial.
Lancet, 353 (1999), pp. 611-616
[19.]
UK Prospective Diabetes Study Group.
Efficacy of atenolol and captopril in reducing risk of macrovascular complications in type 2 diabetes: UKPDS 39.
BMJ, 317 (1998), pp. 713-720
[20.]
L. Hansson, L.H. Lindholm, T. Ekbom, B. Dahloff, J. Lanke, B. Schersten, et al.
Randomised trial of old and new antihypertensivedrugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study.
Lancet, 354 (1999), pp. 1751-1756
[21.]
V. Barrios, J.J. Jiménez.
Corazón e hipertensión.
Nuevas fronteras en hipertensión, pp. 29-63
[22.]
L.M. Ruilope, V. Barrios.
Pharmacologic treatment in hypertensive heart disease, pp. 81-88
[23.]
Z.H. Israili, W.D. Hall.
Cough and angioneurotic edema associatedwith angiotensin-converting-enzyme inhibitor therapy: a review ofthe literature and pathophysiology.
An Intern Med, 117 (1992), pp. 234-242
[24.]
B.S. Bloom.
Continuation of initial antihypertensive medication after1 year of therapy.
Clin Ther, 20 (1998), pp. 671-681
[25.]
P.R. Conlin, W.C. Gerth, J. Fox, J.B. Roehm, S.J. Boccuzzi.
Four-yearpersistence patterns among patients initiating therapy with theangiotensin II receptor antagonist losartan versus other antihypertensivedrug classes.
Clin Ther, 23 (2001), pp. 1999-2010
[26.]
R.Z. Paster, D.B. Snavely, A.R. Swett, R.A. Draper, A.I. Goldberg, B.A. Soffer, et al.
Use of losartan in the treatment of hypertensive patientswith a history of cough induced by angiotensin-converting-enzymeinhibitors.
Clin Ther, 20 (1998), pp. 978-989
[27.]
H.R. Black, A. Graff, D. Shute, R. Stoltz, D. Ruff, J. Levine, et al.
Valsartan,a new angiotensin II antagonist of the treatment of essentialhypertension. Efficacy, tolerability and safety compared to anangiotensin inhibitor, lisinopril.
J Hum Hypertens, 11 (1997), pp. 483-489
[28.]
G. Belcher, R. Hubner, M. George, D. Elmfeldt, H. Lunde.
Candersartancilexetil: safety and tolerability in healthy volunteers and patientswith hypertension.
J Hum Hypertens, 11 (1997), pp. 585-589
[29.]
V. Barrios, A. Navarro, A. Esteras, M. Luque, J. Romero, J. Tamargo, et al.
Antihypertensive efficacy and tolerability of lercarnidipine indaily clinical practice. The ELYPSE study.
Blood Pressure, 11 (2002), pp. 95-100
[30.]
P. Sever.
Candersartan cilexetil: a new, long-acting, effective angiotensinII type I receptor blocker.
J Hum Hypertens, 11 (1997), pp. 591-595
[31.]
C.I. Johnston.
Angiotensin receptor antagonist: focus on losartan.
Lancet, 346 (1995), pp. 1403-1407
[32.]
J.C. Gillis, A. Markham.
Irbesartan: a review of its pharmacodynamicand pharmacokinetic properties and therapeutic use in themanagement of hypertension.
Drugs, 54 (1997), pp. 885-890
[33.]
A. Markham, K.L. Goa.
Valsartan: a review of its pharmacology andtherapeutic use in essential hypertension.
Drugs, 54 (1997), pp. 299-311
[34.]
H.R. Black, A. Graff, D. Shute, R. Stolz, D. Ruff, J. Levine, et al.
Valsartan,a new angiotensin II antagonist for the treatment of essentialhypertension. Efficacy, tolerability and safety compared to anangiotensin-converting enzyme inhibitor, lisinopril.
J Hum Hypertens, 11 (1997), pp. 483-489
[35.]
I. Tikkanen, P. Omvik, H.A. Jensen, For the Scandinavian StudyGroup.
Comparison of the angiotensin II antagonist losartan withthe angiotensin converting enzyme inhibitor enalapril in patientswith essential hypertension.
J Hypertens, 13 (1995), pp. 1343-1351
[36.]
A. Mimran, L.M. Ruilope, L. Kerwin, M. Nys, D. Owens, K. Kassler-Taub, et al.
A randomised, double blind comparison of the angiotensinII receptor antagonist irbesartan, with the full dose range ofenalapril for the treatment of mild-to-moderate hypertension.
JHum Hypertens, 12 (1998), pp. 203-208
[37.]
B.E. Karlberg, L.E. Lins, K. Hermansson, For the TEES Study Group.
Efficacy and Safety of Telmisartan, a selective AT I receptor antagonist, compared with enalapril in elderly patients with Primaryhypertension.
J Hypertens, 17 (1999), pp. 293-302
[38.]
B. Dahlof, S. Keller, L. Makris, A.I. Goldberg, C.S. Sweet, N.Y. Lim.
Efficacyand tolerability of losartan potassium and atenolol in patientswith mild or moderate essential hypertension.
Am J Hypertens, 8 (1995), pp. 578-583
[39.]
L. Corea, O. Cardoni, R. Fogari, P. Innocenti, C. Porcellati, M. Providenza, et al.
Valsartan, a new angiotensin II antagonist for the treatmentof essential hypertension. A comparative study of the efficacyand safety agonist amlodipine.
Clin Pharm Ther, 60 (1996), pp. 341-346
[40.]
F. Lombera, V. Barrios, F. Soria, L. Placer, J.M. Cruz, L. Tomás.
Guías de práctica clínica de la Sociedad Española de Cardiologíaen hipertensión arterial.
Rev Esp Cardiol, 53 (2000), pp. 66-90
[41.]
American Diabetes Association.
Diabetic nephropathy.
DiabetesCare, 25 (2002), pp. S85-S89
[42.]
D. Fliser, K. Buchholz, H. Haller.
For the European Trial on Olmesartanand Pravastatin in Inflammation and Atherosclerosis (EUTOPIA)Investigators. Antiinflammatory effects of angiotensin IIsubtype 1 receptor blockade in hypertensive patients with microinflammation.
Circulation, 110 (2004), pp. 1103-1107
[43.]
K. Kassler-Taub, T. Little John, W. Elliott, T. Ruddy, E. Adler.
Comparativeefficacy of two angiotensin II receptor antagonists, irbersartanand losartan, in mild to moderate hypertension.
Am J Hypertens, 11 (1998), pp. 445-453
[44.]
O.K. Andersson, S. Neldom.
The antihypertensive effect and tolerabilityof candersartan cilexetil, a new generation angiotensin II antagonist,in comparison with losartan.
Blood Press, 7 (1998), pp. 53-59
[45.]
S. Oparil.
Comparative antihypertensive efficacy of olmesartan:comparison with other angiotensin II receptor antagonists.
J HumHypertens, 16 (2002), pp. 17-23
[46.]
P. Conlin, B. Spence, A. Ribeiro, I. Saito, C. Benedict, M. Bunt.
AngiotensinII antagonist for hypertension: are there differences in efficacy?.
Am J Hypertens, 13 (2000), pp. 418-426
[47.]
L. Hansson, L.H. Lindholm, L. Niskanen, J. Lanke, T. Hedner, A. Niklason, et al.
Effect angiotensin-converting-enzyme inhibition comparedwith conventional therapy on cardiovascular morbidity andmortality in hypertension: Captopril Prevention Project (CAPPP)randomised trial.
Lancet, 353 (1999), pp. 611-616
[48.]
M.J. Brown, C.R. Palmer, A. Castaigne, P.W. De Leeuw, G. Mancia, T. R.osenthal, et al.
Morbidity and mortality in patients randomised todouble-blind treatment with a long-acting calcium-channel blockeror diuretic in the International Nifedipine GITS study: interventionas a goal in hypertension treatment (INSIGHT).
Lancet, 356 (2000), pp. 366-372
[49.]
L. Hansson, T. Hedner, P. Lund-Johansen, S. Kjeldsen, L.H. Lindholm, J.O. Syvertsen, et al.
Randomised trial of effects of calcium antagonistscompared with diuretics and Beta-blockers on cardiovascularmorbidity and mortality in hypertension: the Nordic Diltiazem(NORDIL) study.
Lancet, 356 (2000), pp. 359-365
[50.]
L. Hansson, L.H. Lindholm, T. Ekbom, B. Dahlof, J. Lanke, B. Schersten, et al.
Randomised trial of old and new antihypertensive drugsin elderly patients: cardiovascular mortality and morbidity theSwedish Trial in Old Patients with Hypertension-2-study.
Lancet, 354 (1999), pp. 1751-1756
[51.]
E.J. Lewis, L.G. Hunsicker, W.R. Clarke, T. Berl, M.A. Pohl, J.B. Lewis, Collaborative Study Group., et al.
Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathydue to type 2 diabetes.
N Engl J Med, 345 (2001), pp. 851-860
[52.]
B.M. Brenner, M.E. Cooper, D. De Zeeuw, W.F. Keane, W.E. Mitch, H.H. Parving, et al.
Effects of losartan on renal and cardiovascularoutcomes in patients with type 2 diabetes and nephropathy.
NEngl J Med, 345 (2001), pp. 861-869
[53.]
B. Dahlof, R.B. Devereux, S.E. Kjeldsen, S. Julius, G. Beevers, U. De Faire, For the LIFE Study Group.
Cardiovascular morbidity andmortality in the Losartan Intervention For Endpoint reduction inhypertension study (LIFE): a randomised trial against atenolol.
Lancet, 359 (2002), pp. 995-1003
[54.]
P.M. Okin, R.B. Devereux, S. Jern, S.E. Kjensen, S. Julius, M. Nieminen, et al.
The Losartan Intervention for Endpoint reduction in hypertension(LIFE) Study. Regression of electrocardiographic leftventricular hypertrophy by losartan versus atenolol.
Circulation, 108 (2003), pp. 684-690
[55.]
R.B. Devereux, B. Palmieri, J. Liu, C. Wachtell, J. Bella, K. Boman, et al.
Progressive hypertrophy regression with sustained pressure reductionin hypertension: the Losartan Intervention For EndpointReduction study.
J Hypertens, 20 (2002), pp. 1445-1450
[56.]
R.B. Devereux, B. Dahlof, E. Gerdts, K. Boman, M. Nieminen, V. Papademetriou, et al.
The Losartan Intervention for Endpoint reductionin hypertension (LIFE) Trial. Regression of hypertensive leftventricular hypertrophy by losartan compared with atenolol.
Circulation, 110 (2004), pp. 1456-1462
[57.]
B. Dahlof, A. Zanchetti, J. Díez, M.G. Nicholls, C.H.M. Yu, V. Barrios, For the REGAAL Study Investigators.
Effects of losartan andatenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy.
J Hypertens, 20 (2002), pp. 1855-1864
[58.]
L.H. Lindholm, H. Ibsen, B. Dahlof, R.B. Devereux, G. Beevers, U. De Faire, et al.
Cardiovascular morbidity and mortality in diabetics patients of the LIFE study: a randomised trial against atenolol.
Lancet, 359 (2002), pp. 1004-1010
[59.]
L.H. Linholm, B. Dahlof, J.M. Edelman, H. Ibsen, K. Borch Johnsen, M.H. Olsen, et al.
Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study.
Lancet, 362 (2003), pp. 619-620
[60.]
S. Kjeldsen, B. Dahlof, R. Devereux, S. Julius, P. Aurup, J. Edelman, For the LIFE study, et al.
Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy. A Losartan Intervention For Endpoint Reduction (LIFE) Substudy.
JAMA, 288 (2002), pp. 1491-1498
[61.]
K. Wachtell, V. Palmieri, M.H. Olsen, E. Gerdts, V. Papademetriou, M.S. Nieminen, et al.
Change in systolic left ventricular performance after 3 years of antihypertensive treatment: the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study.
Circulation, 106 (2002), pp. 227-232
[62.]
K. Wachtell, J.N. Bella, J. Rokkedal, V. Palmieri, V. Papademetriou, B. Dahlöf, et al.
Change in diastolic left ventricular filling after one year of antihypertensive treatment: the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study.
Circulation, 105 (2002), pp. 1071-1076
[63.]
E. Gerdts, V. Papademetriou, V. Palmieri, K. Boman, H. Bjornstad, K. Wachtell.
Correlates of pulse pressure reduction during antihypertensive treatment (losartan or atenolol) in hypertensive patients with electrocardiographic left ventricular hypertrophy (the LIFE Study).
Am J Cardiol, 89 (2002), pp. 399-402
[64.]
E. Gerdts, L. Oikarinen, V. Palmieri, J.E. Otterstad, K. Wachtell, K. Boman, et al.
Correlates of left atrial size in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study.
Hypertension, 39 (2002), pp. 739-743
[65.]
K. Wachtell, M.H. Olsen, B. Dahlof, R.B. Devereux, S.E. Kjeldsen, M.S. Nieminen, et al.
Microalbuminuria in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE Study.
J Hypertens, 20 (2002), pp. 405-412
[66.]
K. Wachtell, H. Ibsen, M. Olsen, K. Borch-Johnsen, L.H. Lindholm, C.E. Mogensen, et al.
Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study.
Ann Intern Med, 139 (2003), pp. 901-906
[67.]
R.B. Devereux, B. Dahlof, S.E. Kjeldsen, S. Julius, P. Aurup, G. Beepers, et al.
Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trial.
Ann Intern Med, 139 (2003), pp. 169-177
[68.]
V. Barrios, R. Campuzano, G. Peña, G. Guzmán, L.M. Ruilope.
Estratificación del riesgo cardiovascular en hipertensión en atención primaria e impacto sobre el tratamiento antihipertensivo. Estudio DIORISC.
Hipertensión, 19 (2002), pp. 114-120
[69.]
H.H. Parving, H. Lehnert, J. Brochner-Mortensen, R. Gomis, S. Andersen, P. Arner.
Irbesartan in patients with type 2 diabetes and microalbuminuria study group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.
N Engl J Med, 345 (2001), pp. 870-878
[70.]
L. Hansson, H. Lithell, I. Skoog, F. Baro, C.M. Bánki, M. Breteler, et al.
Study on cognition and prognosis in the elderly (SCOPE): baseline characteristics.
Blood Press, 9 (2000), pp. 146-151
[71.]
H. Lithell, L. Hansson, I. Skoog, D. Elmfeldt, A. Hofman, B. Olofsson, et al.
The study on cognition and prognosis in the elderly (SCOPE): principal results of a randomized double-blind intervention trial.
J Hypertens, 21 (2003), pp. 875-886
[72.]
H. Lithell, L. Hansson, I. Skoog, D. Elmfeldt, A. Hofman, B. Olofsson, et al.
The study on cognition and prognosis in the elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomisation.
J Hypertens, 22 (2004), pp. 1605-1612
[73.]
V. Papademetriou, C. Farsang, D. Emfeldt, A. Hofman, H. Lithell, B. Olofsson, et al.
Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the study on Cognition and Prognosis in the Elderly (SCOPE).
J Am Coll Cardiol, 44 (2004), pp. 1175-1180
[74.]
J. Mann, S. Julius, For the VALUE Trial Group.
The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design.
Blood Press, 7 (1998), pp. 176-183
[75.]
S.E. Kjeldsen, S. Julius, H. Brunner, L. Hansson, M. Henis, S. Ekman, et al.
Characteristics of 15,314 hypertensive patients at high coronary risk. The VALUE trial. The valsartan antihypertensive longterm use evaluation.
Blood Press, 10 (2001), pp. 83-91
[76.]
S. Julius, S.E. Kjeldsen, M. Weber, H. Brunner, S. Ekman, L. Hansson, et al.
Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.
Lancet, 363 (2004), pp. 2022-2031
[77.]
J.A. Staessen, J.G. Wang, L. Thijs.
Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 march 2003.
J Hypertens, 21 (2003), pp. 2865-2876
[78.]
J.L. Pool, R. Glazer, Y.T. Chiang, M. Gatlin.
Dose-response efficacy of valsartan, a new angiotensin II receptor blocker.
J Hum Hypertens, 13 (1999), pp. 275-281
[79.]
P. Verdechia, G. Reboldi, F. Angeli, C. Borgioni, R. Gattobigio, L. Filippucci, et al.
Adverse prognostic significance of new diabetes in treated hypertensive subjects.
Hypertension, 43 (2004), pp. 963-969
[80.]
D. Aguilar, S.D. Salomon, L. Kober, J.L. Rouleau, H. Skali, J.J. McMurray, et al.
Newly diagnosed and previously known diabetes mellitus and 1-year outcomes of acute myocardial infarction: the Valsartan in acute myocardial infarction (VALIANT) Trial.
Circulation, 110 (2004), pp. 1572-1578
[81.]
M. Weber, S. Julius, S.E. Kjeldsen, H. Brunner, S. Ekman, L. Hansson, et al.
Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial.
Lancet, 363 (2004), pp. 2049-2051
Copyright © 2005. Sociedad Española de Arteriosclerosis y Elsevier España S.L.